Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants

American Journal of Transplantation

Volumn 17, Issue 11, 2017, Pages 2945-2954

  Chandran, S ^a   Tang, Q ^a,b   Sarwal, M ^a   Laszik, Z G ^a   Putnam, A L ^b   Lee, K ^a   Leung, J ^a   Nguyen, V ^a   Sigdel, T ^a   Tavares, E C ^a   Yang, J Y C ^a   Hellerstein, M ^c   Fitch, M ^c   Bluestone, J A ^b   Vincenti, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cellular biology; clinical trial; immune regulation; immunobiology; immunosuppressant polyclonal preparations; kidney transplantation nephrology; protocol biopsy; rejection: subclinical; translational research science

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; DEUTERIUM; GLUCOSE; MYCOPHENOLIC ACID; STEROID; TACROLIMUS; ALLOANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CASE REPORT; CELL DENSITY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; EX VIVO STUDY; FEASIBILITY STUDY; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY GRAFT; LIMIT OF DETECTION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEROID THERAPY; ADOLESCENT; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DONOR; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; PATHOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INFLAMMATION; ISOANTIGENS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; YOUNG ADULT;

EID: 85032276992     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14415     Document Type: Article

References (30)

1. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527–535.
2. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563–570.
3. Thierry A, Thervet E, Vuiblet V, et al. Long-term impact of subclinical inflammation diagnosed by protocol biopsy one year after renal transplantation. Am J Transplant 2011; 11: 2153–2161.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242–249.
5. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713–723.
6. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753–760.
7. Hoffmann SC, Hale DA, Kleiner DE, et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573–581.
8. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747–752.
9. Park WD, Griffin MD, Cornell LD, Cosio FG, Stegall MD. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987–1997.
10. Feng Y, van der Veeken J, Shugay M, et al. A mechanism for expansion of regulatory T-cell repertoire and its role in self-tolerance. Nature 2015; 528: 132–136.
11. Tang Q, Bluestone JA. The Foxp3 + regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 2008; 9: 239–244.
12. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015; 7: 315ra189
13. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; 117: 3921–3928.
14. Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol 2014; 153: 23–30.
15. Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. Hepatology 2016; 64: 632–643.
16. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342–2351.
17. Taflin C, Nochy D, Hill G, et al. Regulatory T cells in kidney allograft infiltrates correlate with initial inflammation and graft function. Transplantation 2010; 89: 194–199.
18. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: Moving to the clinic. Cold Spring Harb Perspect Med 2013; 3.
19. Chesneau M, Michel L, Dugast E, et al. Tolerant kidney transplant patients produce B cells with regulatory properties. J Am Soc Nephrol 2015; 26: 2588–2598.
20. Braza F, Dugast E, Panov I, et al. Central role of CD45RA- Foxp3hi memory regulatory T cells in clinical kidney transplantation tolerance. J Am Soc Nephrol 2015; 26: 1795–1805.
21. Kang SM, Tang Q, Bluestone JA. CD4 + CD25 + regulatory T cells in transplantation: Progress, challenges and prospects. Am J Transplant 2007; 7: 1457–1463.
22. Naesens M, Salvatierra O, Benfield M, et al. Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation. Am J Transplant 2012; 12: 2730–2743.
23. Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009; 58: 652–662.
24. Bestard O, Cruzado JM, Rama I, et al. Presence of FoxP3 + regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19: 2020–2026.
25. Berglund D, Korsgren O, Lorant T, Schneider K, Tufveson G, Carlsson B. Isolation, expansion and functional assessment of CD4 + CD25 + FoxP3 + regulatory T cells and Tr1 cells from uremic patients awaiting kidney transplantation. Transpl Immunol 2012; 26: 27–33.
26. Guinan EC, Cole GA, Wylie WH, et al. Ex vivo costimulatory blockade to generate regulatory T cells from patients awaiting kidney transplantation. Am J Transplant 2016; 16: 2187–2195.
27. Singh K, Stempora L, Harvey RD, et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. Am J Transplant 2014; 14: 2691–2703.
28. Hu M, Wang YM, Wang Y, et al. Regulatory T cells in kidney disease and transplantation. Kidney Int 2016; 90: 502–514.
29. Komatsu N, Okamoto K, Sawa S, et al. Pathogenic conversion of Foxp3 + T cells into TH17 cells in autoimmune arthritis. Nat Med 2014; 20: 62–68.
30. Rossetti M, Spreafico R, Saidin S, et al. Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J Immunol 2015; 194: 113–124.